比较依奇珠单抗治疗银屑病关节炎两项III期临床试验中复合指标的表现
本研究分析SPIRIT-P1和SPIRIT-P2两项III期试验数据,评估依奇珠单抗治疗银屑病关节炎时MDA/VLDA、DAPSA、PASDAS、GRACE和mCPDAI等复合指标的表现。第24周时依奇珠单抗组达到治疗目标的患者显著多于安慰剂组,mCPDAI和DAPSA评估达标者更多但残留高患者报告结局和功能残疾更常见。高基线结构损伤和功能残疾降低所有复合指标的应答率,对MDA/VLDA影响最突出。
要点
- 第24周依奇珠单抗组用所有复合指标评估的达标率均显著高于安慰剂组。
- mCPDAI和DAPSA评估的达标率高于其他复合指标,但残留高PROs和功能残疾更常见。
- 高基线结构损伤和功能残疾降低所有复合指标应答率,对MDA/VLDA影响最突出。
核心结论
- 达标患者中残留疾病活动度在各复合指标间相似,但mCPDAI和DAPSA评估时残留高PROs和功能残疾更常见,最可能因这些复合指标缺少或减弱功能评估。
- 高基线结构损伤和功能残疾削弱所有复合指标的应答率,对MDA/VLDA影响最突出;作者认为在这些患者中LDA可能是最合适的目标。
研究设计与样本
- 分析SPIRIT-P1和SPIRIT-P2两项III期临床试验数据,评估依奇珠单抗对MDA/VLDA、DAPSA、PASDAS、GRACE和mCPDAI复合指标达标的影响。
- 通过量化残留症状负担以及结构损伤和功能残疾的影响来比较各复合指标的表现。
主要发现
- 第24周时,依奇珠单抗治疗组达到治疗目标的患者显著多于安慰剂组(所有复合指标评估)。
- 用mCPDAI和DAPSA评估达标者多于其他复合指标。
- 各复合指标间残留疾病活动度相似,但mCPDAI和DAPSA评估时残留高PROs和功能残疾更频繁。
- 高基线结构损伤和功能残疾降低治疗目标达标率。
临床怎么用
- 作者认为,在高基线结构损伤和功能残疾的患者中,LDA可能是最合适的目标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVE: The aim of this study was to evaluate relative performance of composite measures in psoriatic arthritis and assess the impact of structural damage and functional disability on outcomes during ixekizumab treatment. METHODS: Data from SPIRIT-P1 and SPIRIT-P2 were analysed to evaluate the effect of ixekizumab on achievement of low disease activity (LDA) and remission with the minimal disease activity (MDA) and very low disease activity (VLDA) composite, Disease Activity index for Psoriatic Arthritis (DAPSA), Psoriatic Arthritis Disease Activity Score, GRAppa Composite ScorE and modified Composite Psoriatic Disease Activity Index (mCPDAI). Performance was compared by quantifying residual symptom burden and the impact of structural damage and functional disability. RESULTS: Significantly more ixekizumab-treated patients achieved treatment targets at week 24 versus placebo assessed with all composites. More patients achieved targets assessed by mCPDAI and DAPSA than other composites. Residual disease activity was similar between composites, but residual high patient-reported outcomes (PROs) and functional disability were more frequent when assessed with mCPDAI and DAPSA. Achievement of treatment targets was reduced by high baseline levels of structural damage and functional disability. CONCLUSION: Residual disease activity was similar in patients achieving treatment targets assessed with all composites, but residual high PROs and functional disability were more common when assessed with mCPDAI and DAPSA, most likely due to the absence/attenuated functional assessment in these composites. High baseline levels of structural damage and functional disability attenuated response rates with all composites, affecting MDA/VLDA most prominently; LDA may be the most appropriate target in these patients. TRIAL REGISTRATION NUMBER: NCT01695239.
引用
- Coates LC, Smolen JS, Mease PJ, et al. Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis. RMD Open. 2022. PMID: 36171019. doi:10.1136/rmdopen-2022-002457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。